Dennis Hallahan, MD, FASTRO, and Abhay Singh, PhD have been awarded a grant from the Needleman Program for Innovation & Commercialization for $328,340. Their work is entitled “Bispecific T Cell effectors targeting an inducible cancer cell surface antigen”.
Hallahan and Singh awarded Needleman grant
